Officials defend swine flu vaccination plan1111111111111111111

WASHINGTON (Reuters) - U.S. public health officials defended the distribution of swine flu vaccines on Tuesday against criticism that their plan to protect Americans was confusing and over-optimistic.

Manufacturers have delivered 48.5 million doses of H1N1 vaccine, Dr. Anne Schuchat of the U.S. Centers for Disease Control and Prevention told a Senate hearing. HHS had hoped to have as many as 120 million doses by now.

The problem was worsened because the first vaccine to be available was a nasal spray made by AstraZeneca unit MedImmune that is not suitable for some of the most vulnerable groups but which is perfect for most schoolchildren and healthcare workers, officials said.

Members of the Senate Homeland Security and Governmental Affairs Committee pressed for an apology and said they felt President Barack Obama's administration had not learned some valuable lessons from the continuing problem.

"I am worried that we are undermining confidence in our public health system," said committee chairman, Connecticut independent Sen. Joseph Lieberman.

He said he feared people who have waited in vain to be vaccinated against H1N1 swine flu will stop trying.

"This hearing is critical to peeling away the layers of misinformation and miscommunication that has hampered the federal government's pandemic influenza strategy," added Maine Republican Senator Susan Collins.

The U.S. government is struggling to vaccinate as many people as possible against the virus, which has infected an estimated 22 million Americans and killed 3,900.

In September HHS Secretary Kathleen Sebelius had assured Congress, "There will be enough vaccines for everyone."

"I think we led expectations of availability to be higher than they have been. I think that led to frustration," Schuchat said.

ADMITTING MISTAKES

"I think you used the word mistake and it is important to acknowledge that here," Lieberman said.

HHS spokeswoman Jenny Backus later said Sebelius's promise was not a mistake.

"The problem has been that lots of people want it all at the same time and that has been a challenge and we understand that people are frustrated," Backus said by email.

"Vaccine came off the production lines slower than what the original predictions were and we made the tough choice to start the vaccination program as soon as vaccine was ready to go even though we knew that supplies would be low